Literature DB >> 579295

Prolactin oversuppression.

H G Bohnet, D Mühlenstedt, J P Hanker, H P Schneider.   

Abstract

Patients with primary infertility due to hyperprolactinemic corpus luteum insufficiency and oligomenorrhea were treated with Bromocriptin. Suppression of serum prolactin for up to four menstrual cycles resulted in a normalisation of the length of the cycle(32 vs 28 days) as well as of luteal progesterone secretion. In addition, ovulation occurred earlier after than before treatment (on day 14 vs day 18). When, however, prolactin concentrations reached levels of less than 120 muU/ml (3 ng/ml), which were observed during the 5th and 6th treatment course, reappearance of shortened luteal phase occurred probably due to oversuppression of prolactin. Premenstrual spottings were observed too. The data presented indicate that minimal prolactin is required for normal follicular maturation and luteal development. On the other hand, the gonadostat may be susceptable to the dopaminergic stimulus of Bromocriptin to a different extent as oversuppression of prolactin is not observed in hyperprolactinemic anovulatory syndromes. Thus, treatment with Bromocriptin requires a continuous monitoring of serum prolactin as well as individual treatment regimens.

Entities:  

Keywords:  Biology; Clinical Research; Endocrine System; Hormones; Infertility; Menstrual Cycle; Menstruation; Physiology; Pituitary Hormones; Progestational Hormones; Progesterone--analysis; Prolactin--analysis; Reproduction; Research Methodology

Mesh:

Substances:

Year:  1977        PMID: 579295     DOI: 10.1007/bf00667386

Source DB:  PubMed          Journal:  Arch Gynakol        ISSN: 0003-9128


  13 in total

1.  A possible role for prolactin in control of steroid secretion by the human Graafian follicle.

Authors:  K P McNatty; R S Sawers; A S McNeilly
Journal:  Nature       Date:  1974-08-23       Impact factor: 49.962

2.  Psychological factors, psychiatric illness and amenorrhoea after oral contraceptive treatment.

Authors:  H Fries; S J Nillius
Journal:  Acta Psychiatr Scand       Date:  1973-07       Impact factor: 6.392

3.  Incidence and significance of hyperprolactinaemia in women with amenorrhea.

Authors:  S Franks; M A Murray; A M Jequier; S J Steele; J D Nabarro; H S Jacobs
Journal:  Clin Endocrinol (Oxf)       Date:  1975-11       Impact factor: 3.478

4.  The use of bromocriptine in the galactorrhoea-amenorrhoea syndromes: the Canadian cooperative study.

Authors:  H G Friesen; G Tolis
Journal:  Clin Endocrinol (Oxf)       Date:  1977       Impact factor: 3.478

5.  Effect of prolactin on LH receptor in rat luteal cells.

Authors:  J A Holt; J S Richards; A R Midgley; L E Reichert
Journal:  Endocrinology       Date:  1976-04       Impact factor: 4.736

6.  Hyperprolactinaemia and luteal insufficiency.

Authors:  M Seppälä; T Ranta; E Hirvonen
Journal:  Lancet       Date:  1976-01-31       Impact factor: 79.321

7.  Hyperprolactinemic anovulatory syndrome.

Authors:  H G Bohnet; H G Dahlén; W Wuttke; H P Schneider
Journal:  J Clin Endocrinol Metab       Date:  1976-01       Impact factor: 5.958

8.  [Hyperprolactinemic amenorrhea. Clinical relevance, endocrine features, therapy (author's transl)].

Authors:  H K Rjosk; K Werder; R Fahlbusch
Journal:  Geburtshilfe Frauenheilkd       Date:  1976-07       Impact factor: 2.915

9.  The influence of the prolactin inhibitor bromocriptin (CB 154) on human luteal function in vivo.

Authors:  K D Schulz; W Geiger; E Del Pozo; K H Lose; H J Künzig; I Lancranjan
Journal:  Arch Gynakol       Date:  1976-09-17

10.  Localization of prolactin binding in prostate and testis: The role of serum prolactin concentration on the testicular LH receptor.

Authors:  C Aragona; H G Bohnet; H G Friesen
Journal:  Acta Endocrinol (Copenh)       Date:  1977-02
View more
  7 in total

1.  [Tumour regression in pituitary adenoma by bromocriptin (author's transl)].

Authors:  D Mühlenstedt; F Osmers; H P Schneider
Journal:  Arch Gynecol       Date:  1978-12-29

Review 2.  Prolactin: role in health and disease.

Authors:  D F Horrobin
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

3.  Effects of synthetic gestagens on serum prolactin and growth hormone secretion in amenorrheic patients.

Authors:  H G Bohnet; N G Naber; E del Pozo; H P Schneider
Journal:  Arch Gynecol       Date:  1978-11-30

4.  [Hyperprolactinemia and sterility].

Authors:  H K Rjosk; R Fahlbusch; K von Werder
Journal:  Arch Gynecol       Date:  1979-07-20

5.  Cabergoline administration prevents development of moderate to severe ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volume.

Authors:  Tomoko Inoue; Shu Hashimoto; Hideyuki Iwahata; Keijiro Ito; Yoshiharu Nakaoka; Yoshiharu Morimoto
Journal:  Reprod Med Biol       Date:  2014-11-11

6.  Serum prolactin and progesterone concentrations in ovulatory infertility.

Authors:  T Ranta; P Lehtovirta; U H Stenman; M Seppälä
Journal:  J Endocrinol Invest       Date:  1979 Jan-Mar       Impact factor: 4.256

7.  Determination and properties of proteohormone receptors in malignant gynecological tumors with special reference to lactogen receptors in human breast cancer.

Authors:  H G Bohnet
Journal:  Arch Gynecol       Date:  1980
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.